MapLight Therapeutics
PublicMapLight Therapeutics is now publicly traded
The data on this page reflects MapLight Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Oct 29, 2025
Last Round
Series D
Jul 28, 2025
Est. Valuation at Exit
$816M
Total Funding Raised
$945.4M
Company Overview
MapLight Therapeutics is a biopharmaceutical company that develops circuit-specific pharmacotherapies for central nervous system disorders using a proprietary platform combining optogenetics, transcriptomics, and spatial biology.
Sector
Biotech
AI Layer
Application
Keywords
MapLight Therapeutics Comparables
Compare MapLight Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Neurosterix | 74% | |
| Tortugas Neuroscience | 74% | |
| Amani Therapeutics | 71% | |
MapLight Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Oct 29, 2025 | ||||
| Series D | Jul 28, 2025 | ||||
| Series C | Oct 30, 2023 | ||||
| Grant | Aug 4, 2021 | ||||
| Series B | Feb 1, 2021 | ||||
Grant | Nov 30, 2020 |
Key People
Founding team and executive leadership
MapLight Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Jefferies | IPO |
| Avego Management | Series D |
| Forbion | Series D |
| Life Sciences at Goldman Sachs Alternatives | Series D |
| TD Securities | Series C |
| Blue Owl Capital | Series D, Series C, Series A, Series B |
| 5AM Ventures | Series D, Series C, Series A, Series B, Seed |
MapLight Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
